UNSPSC 51172110: Prozapine

This classification denotes an antispasmotic agent with the molecular formula C20H25NO2, chemically known as 1-(3,3-diphenylpropyl)azepane hydrochloride but generally known as prozapine hydrochloride, which bears US NIH Compound Identifier 71127. European Medicines Agency schedules Prozapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10154MIG. Most nations schedule prozapine under HS 29339930 and SITC 51577. As of Q4 2014, PROZAPINE remains the US FDA Preferred Term for this commodity.

Prozapine bears US NLM identifiers UMLS ID C0072512 and NCI Concept Code C73167. SMILES: C1CCCN(CC1)CCC(C2=CC=CC=C2)C3=CC=CC=C3.

UNSPSC 51172110 Prozapine is a Commodity code that covers pharmaceutical products used in correctional and criminal-justice supervision contexts. State and local governments solicit this code for specimen collection and drug testing services — including immunoassay screening, confirmatory testing via LC/MS/MS or GC/MS, and alternative methodologies such as oral fluid and hair testing — supplied to support offender monitoring and compliance programs. The work is principally procured by county community supervision and corrections departments, which engage vendors to staff testing collection sites, operate randomized testing notification systems, process specimens, and deliver results electronically under multiyear service agreements. Successful vendors must maintain lab certifications from SAMHSA, state forensic or narcotics divisions, or the College of American Pathologists.

Collin County Community Supervision and Corrections Department issued RFP 2026-327 for Offender Specimen Collection and Drug Testing Services on September 25, 2026, with proposals due July 23, 2026 at 2:00 p.m. The scope encompasses staffing two collection sites in Plano and McKinney during weekday business hours plus five Saturdays annually, processing approximately 25,031 annual tests comprising five-panel and six-panel screens with ancillary testing, and delivering results via electronic reporting. The estimated contract value is $600,000 over two years commencing September 1, 2026, with three optional one-year renewals not to exceed five years total. Pricing is per-test across three service models (screening only, confirmation after screening, and screening with automatic confirmation of positives), and vendors must submit all-inclusive rates covering freight, delivery, insurance, and staffing with no additional surcharges. Award is anticipated August 10, 2026, and will be made to the responsible contractor whose proposal represents the best value considering vendor understanding, firm qualifications, client references, and cost.